2006
DOI: 10.1007/s00277-006-0099-z
|View full text |Cite
|
Sign up to set email alerts
|

Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR–ABL-positive acute lymphoblastic leukemia—retrospective analysis of Polish Adult Leukemia Group (PALG)

Abstract: Patients with Philadelphia chromosome-positive (Ph+) and/or BCR-ABL+ acute lymphoblastic leukemia (ALL) have extremely poor prognoses. Most of these patients have additional, heterogenous karyotype abnormalities, the majority of which have uncertain clinical significance. In this study we analyzed the clinical characteristics, karyotype abnormalities, and outcome of 77 patients with Ph+ and/or BCR-ABL+ ALL registered in Poland in 1997-2004. In 31/55 patients with known karyotype, the sole t(9;22)(q34;q11) abno… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
10
0

Year Published

2006
2006
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(10 citation statements)
references
References 21 publications
0
10
0
Order By: Relevance
“…These remission and survival figures are entirely consistent with previously published, smaller studies. 4,6,13 The factors predicting achievement of CR in our study were age and presenting WBC count.…”
Section: Discussionmentioning
confidence: 71%
“…These remission and survival figures are entirely consistent with previously published, smaller studies. 4,6,13 The factors predicting achievement of CR in our study were age and presenting WBC count.…”
Section: Discussionmentioning
confidence: 71%
“…Translocation (9;22) or the BCR‐ABL fusion gene is detected in approximately 5% to 15% of adolescents, in 25% to 30% of patients aged 25 to 35 years, and in more than 35% to 40% of patients older than 35 years . Historically, treatment results for Ph‐positive ALL were very poor, and a patient's prognosis was dismal . Although complete remission (CR) was obtained in 60% to 90% of patients after first‐line therapy, the relapse rate was very high, and the probability of long‐term survival did not exceed 10% in patients treated with standard chemotherapy and 30% to 35% in those undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) .…”
Section: Introductionmentioning
confidence: 99%
“…The presence of t(9;22) is the hallmark of Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL). Additional chromosomal abnormalities (ACAs) are also present at diagnosis in 40%‐70% of patients with Ph+ ALL . Prior to the routine use of tyrosine kinase inhibitors (TKIs), the presence of ACAs in Ph+ ALL was associated with worse outcomes in some but not all studies.…”
Section: Introductionmentioning
confidence: 99%
“…Additional chromosomal abnormalities (ACAs) are also present at diagnosis in 40%‐70% of patients with Ph+ ALL . Prior to the routine use of tyrosine kinase inhibitors (TKIs), the presence of ACAs in Ph+ ALL was associated with worse outcomes in some but not all studies. In small reports of patients treated with chemotherapy plus imatinib, ACAs have been associated with shorter relapse‐free survival (RFS) and overall survival (OS) .…”
Section: Introductionmentioning
confidence: 99%